Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
HHS-NIH11 Forecasted FOR-TR-27-002Description
The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine. The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) , is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration. Areas of interest for ExTReMe could include, but are not limited to: direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies); designer EVs (personalized to the individual patient’s needs). Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network
Funding Details
- Award Floor
- Not specified
- Award Ceiling
- Not specified
- Total Estimated Funding
- Not specified
- Expected Awards
- Not specified
Key Dates
- Posted
- June 27, 2025
- Closes
- N/A
- Archive Date
- N/A
Agency Information
- Agency Name
- HHS-NIH11
- Agency Code
- HHS-NIH11
- Funding Instrument
- Other